GSTC.US AngioSoma Inc

Healthcare Biotechnology USA Stocks
0.0001 USD
Close of Oct 15, 2026
0.0001 0.0001
Market cap
USD 124K
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2024.

Is GSTC.US undervalued?

Graham number

The Graham number of AngioSoma Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

AngioSoma Inc fundamental analysis

No fundamental analysis for AngioSoma Inc yet.

AngioSoma Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About AngioSoma Inc

GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, engages in the provision of patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases in the United States. The company was formerly known as AngioSoma, Inc. and changed its name to GlobeStar Therapeutics Corporation in July 2021. GlobeStar Therapeutics Corporation is based in New York, New York.

Full company profile